Positive phase III data for risankizumab in adults with active psoriatic arthritis

Two phase III RCTS, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo (KEEPsAKE-1 and KEEPsAKE-2, 57 and 51% of treated patients vs 34 and 27% placebo; p<0.001).

Source:

Biospace Inc.